By Editor , 29 September 2026 Hengrui Licenses Oral GLP-1/GIP Drug to Novo in $2.6B Deal Shanghai – – September 29, 2026 -- Hengrui Pharma has licensed its investigational obesity and diabetes drug HRS-1596 to Novo Nordisk in a deal worth up to 2.6 billion US dollars, including a 300 million dollar upfront payment.
